Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
Lipoatrophy and localized panniculitis have been described as rare complications of daily subcutaneous glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis (MS). We describe the biopsies from two MS patients in a single neurologist's practice who developed clinical lesions of lipoatrophy at the sites of subcutaneous glatiramer acetate injections. These biopsies showed a lobular panniculitis with lipoatrophy that more closely resembled lupus panniculitis than previous reports of localized panniculitis at glatiramer acetate injection sites. In one case, the area of clinical lipoatrophy continued to enlarge for 6 months after stopping glatiramer acetate therapy, before stabilizing at its current size for the last 8 months. Injection site reactions to glatiramer acetate should be considered in the differential diagnosis of biopsies that show a lupus panniculitis-like appearance. Our observations indicate that glatiramer acetate induced panniculitis is common and may continue to progress after therapy has stopped. In this single neurologist's practice, 64% of the patients receiving daily glatiramer acetate injections had clinical evidence of lipoatrophy or panniculitis. Of 100 consecutive patients receiving therapy for MS between February and November 2006, 14 patients were on glatiramer acetate, 9 of whom had clinical lipoatrophy.
Ball
Nigel J
NJ
Department of Pathology, The University of British Columbia and Vancouver General Hospital, Vancouver, British Columbia, Canada. Nigel.Ball@vch.ca
Cowan
Bryce J
BJ
Moore
G R Wayne
GR
Hashimoto
Stanley A
SA
D000273:Adipose Tissue / Q000187:drug effects / Q000473:pathology; D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007279:Injections, Subcutaneous; D008060:Lipodystrophy / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000503:physiopathology; D015434:Panniculitis / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects*
D015703:Antigens, CD; D015415:Biomarkers; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate